Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-045 in Moderate-to-Severe Atopic Dermatitis
2024-520302-19-00Phase 2Withdrawn
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Sep 2025
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing ATI-045 with Placebo (2 arms). Primary endpoint: Percent change from baseline in EASI score at Week 24. Planned start Sep 2025; status: withdrawn.
02
Drugs
bosakitug
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2024-520302-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520302-19-00.